In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy	Metastatic Hormone Naive Prostate Cancer	Active, not recruiting	Phase 2	2025-07-11		NCT04343885

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Advanced Accelerator Applications	11
Australasian Radiopharmaceutical Trials network (ARTnet)	1
Australia's Nuclear Science and Technology Organisation (ANSTO)	1
Australian and New Zealand Urogenital and Prostate Cancer Trials Group	10
Centre for Biostatistics and Clinical Trials (BaCT)	1
Movember Foundation	6
Peter MacCallum Cancer Centre, Australia	48
Prostate Cancer Research Alliance	2
United States Department of Defense	319

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Alfred Hospital	Prahran	Australia	1
Austin Health	Melbourne	Australia	16
Cabrini Hospital	Malvern	Australia	12
Chris O'Brien Lifehouse	Sydney	Australia	8
Fiona Stanley Hospital	Murdoch	Australia	56
Liverpool Hospital	Liverpool	Australia	66
Peter MacCallum Cancer Centre	Melbourne	Australia	149
Royal Adelaide Hospital	Adelaide	Australia	132
Royal Brisbane and Women's Hospital	Brisbane	Australia	23
Royal North Shore	St Leonards	Australia	3
Sir Charles Gairdner Hospital	Nedlands	Australia	43
St Vincent's Hospital Sydney	Sydney	Australia	8